Spectrum Management Group’s ImmunityBio IBRX Stock Holding History

Spectrum Management Group’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-668	Closed	-$16K	–	270
2021 Q1	$16K	Buy	+668	New	+$17.3K	﹤0.01%	188

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Spectrum Management Group's IBRX Position: Q2 2021 in Review

Spectrum Management Group sold out of ImmunityBio (IBRX) in Q2 2021, closing a stake of 668 shares — an estimated $16K sold.

Spectrum Management Group first reported a position in IBRX in Q1 2021 and held it in 1 quarter. The position peaked at $16K in Q1 2021. 125 funds tracked by Wall St. Rank hold IBRX as of Q2 2021.

Spectrum Management Group reported no remaining ImmunityBio position as of Q2 2021 after selling out during the quarter.
Spectrum Management Group sold 668 ImmunityBio shares in Q2 2021, an estimated $16K.
Spectrum Management Group first reported a position in ImmunityBio in Q1 2021 and held it in 1 quarter.
Spectrum Management Group's ImmunityBio position peaked at $16K in Q1 2021.
125 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2021.

Based on Spectrum Management Group's 13F filing for Q2 2021, filed 5 Aug 2021.